Skip to main content
SpringerLink
Log in

Genetic Polymorphisms, Drugs, and Proarrhythmia

  • Published:
Journal of Interventional Cardiac Electrophysiology Aims and scope Submit manuscript

Abstract

Humans vary widely in their response to drug therapy. This may reflect variability in the relationship between a drug dose and the concentrations of drug and metabolite(s) at relevant target sites; this is termed pharmacokinetic variability. Another mechanism is that individuals vary in their response to identical exposures to drug (pharmacodynamic variability). In this case, there may be variability in the target molecule(s) with which a drug interacts, or more generally in the broad biologic context in which the drug-target interaction occurs; for example, ischemia, electrolyte disturbances, or hypertrophy can all modulate drug effects. Variants in the genes encoding proteins important for pharmacokinetics or for pharmacodynamics have now been described as important contributors to variable drug actions, including proarrhythmia, and are described here. These increasingly well-recognized examples have two important implications; first, it may be possible to develop drugs devoid of heretofore-unexplained adverse effects and, second, it may become possible to preselect drug for individual patients based on specific genetic factors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Roden DM, Kim RB. Pharmacokinetics, pharmacodynamics, pharmacogenetics, and drug interactions. In: Zipes DP, Jalife J, eds. Cardiac Electrophysiology: From Cell to Bedside. Philadelphia: W.B. Saunders, 2000:882–890.

    Google Scholar 

  2. Kalow W. Pharmacogenetics—Heredity and Responses to Drugs. Philadelphia: W.B. Saunders, 1962.

    Google Scholar 

  3. Hill MR, Gotz VP, Harman E, McLeod I, Hendeles L. Evaluation of the asthmogenicity of propafenone, a new antiarrhythmic drug: Comparison of spirometry with methacholine challenge. Chest 1986;90:698–702.

    Google Scholar 

  4. Lee JT, Kroemer HK, Silberstein DJ, Funck-Brentano C, Lineberry MD, Wood AJ, Roden DM, Woosley RL. The role of genetically determined polymorphic drug metabolism in the beta-blockade produced by propafenone. N Engl J Med 1990;322:1764–1768.

    Google Scholar 

  5. Meyer UA, Zanger UM. Molecular mechanisms of genetic polymorphisms of drug metabolism. Annual Review of Pharmacology & Toxicology 1997;37:269–296.

    Google Scholar 

  6. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, Maurel P, Relling M, Brimer C, Yasuda K, Venkataramanan R, Strom S, Thummel K, Boguski MS, Schuetz E. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001;27:383–391.

    Google Scholar 

  7. Priori SG. Exploring the hidden danger of noncardiac drugs. J Cardiovasc Electrophysiol 1998;9:1114–1116.

    Google Scholar 

  8. Roden DM. Point of view: Acquired long QT syndromes and the risk of proarrhythmia. J Cardiovasc Electrophysiol 2000;11:938–940.

    Google Scholar 

  9. Keating MT, Sanguinetti MC. Molecular and cellular mechanisms of cardiac arrhythmias. Cell 2001;104:569–580.

    Google Scholar 

  10. Marx SO, Kurokawa J, Reiken S, Motoike H, D'Armiento J, Marks AR, Kass RS. Requirement of a macromolecular signaling complex for beta adrenergic receptor modulation of the KCNQ1-KCNE1 potassium channel. Science 2002;295:496–499.

    Google Scholar 

  11. Sesti F, Abbott GW, Wei J, Murray KT, Saksena S, Schwartz PJ, Priori SG, Roden DM, George AL, Jr., Goldstein SA. A common polymorphism associated with antibiotic-induced cardiac arrhythmia. Proc Natl Acad Sci USA 2000;97:10613–10618.

    Google Scholar 

  12. Kupershmidt S, Yang IC, Sutherland M, Wells KS, Yang T, Yang P, Balser JR, Roden DM. The cardiac-enriched LIM domain protein FHL2 is required to generate I Ks in a heterolgous system. FASEB J, accepted for publication.

  13. Yang IC, Kupershmidt S, Wei J, Petersen CI, Johns DC, George AL, Jr., Roden DM, Balser JR. A molecular toggle for drug block of HERG potassium channels. Circulation 2000;102:260.

    Google Scholar 

  14. Wang SM, Morales MJ, Liu SG, Strauss HC, Rasmusson RL. Time, voltage, and ionic concentration dependence of rectification of h-erg expressed in Xenopus oocytes. FEBS Lett 1996;389:167–173.

    Google Scholar 

  15. Yang T, Snyders DJ, Roden DM. Rapid inactivation determines the rectification and [K+]o dependence of the rapid component of the delayed rectifier K+ current in cardiac cells. Circ Res 1997;80:782–789.

    Google Scholar 

  16. Numaguchi H, Johnson JP, Jr., Petersen CI, Balser JR. A sensitive mechanism for cation modulation of potassium current. Nat Neurosci 2000;3:429–430.

    Google Scholar 

  17. Mitcheson JS, Chen J, Lin M, Culberson C, Sanguinetti MC.A structural basis for drug-induced long QT syndrome. Proc Natl Acad Sci USA 2000;97:12329–12333.

    Google Scholar 

  18. Roden DM. Taking the idio out of idiosyncratic—Predicting torsades de pointes. PACE 1998;21:1029–1034.

    Google Scholar 

  19. Donger C, Denjoy I, Berthet M, Neyroud N, Cruaud C, Bennaceur M, Chivoret G, Schwartz K, Coumel P, Guicheney P. KVLQT1 C-terminal missense mutation causes a forme fruste long-QT syndrome. Circulation 1997;96:2778–2781.

    Google Scholar 

  20. Napolitano C, Schwartz PJ, Brown AM, Ronchetti E, Bianchi L, Pinnavaia A, Acquaro G, Priori SG. Evidence for a cardiac ion channel mutation underlying drug-induced QT prolongation and life-threatening arrhythmias. J Cardiovasc Electrophysiol 2000;11:691–696.

    Google Scholar 

  21. Yang P, Kanki H, Drolet B, Yang T, Wei J, Viswanathan PC, Hohnloser SH, Shimizu W, Schwartz PJ, Stanton MS, Murray KT, Norris K, George ALJ, Roden DM. Allelic variants in Long QT disease genes in patients with drug-associated Torsades de Pointes. Circulation 2002;105: 1943–1948.

    Google Scholar 

  22. Wei J, Yang IC, Tapper AR, Murray KT, Viswanathan P, Rudy Y, Bennett PB, Norris K, Balser JR, Roden DM, George AL. KCNE1 polymorphism confers risk of drug-induced long QT syndrome by altering kinetic properties of IKs potassium channels. Circulation 1999;I-495.

  23. Splawski I, Timothy KW, Tateyama M, Clancy CE, Malhotra A, Beggs AH, Cappuccio FP, Sagnella GA, Kass RS, Keating MT. Variant of SCN5A sodium channel implicated in risk of cardiac arrhythmia. Science 2002;297: 1333–1336.

    Google Scholar 

  24. Alings M, Wilde A. “Brugada” syndrome: Clinical data and suggested pathophysiological mechanism. Circulation 1999;99:666–673.

    Google Scholar 

  25. Chen QY, Kirsch GE, Zhang DM, Brugada R, Brugada J, Brugada P, Potenza D, Moya A, Borggrefe M, Breithardt G, Ortizlopez R, Wang Z, Antzelevitch C, Obrien RE, Schulzebahr E, Keating MT, Towbin JA, Wang.Genetic basis and molecular mechanism for idiopathic—ventricular fibrillation. Nature 1998;392:293–296.

    Google Scholar 

  26. Roden DM. The problem, challenge, and opportunity of genetic heterogeneity in monogenic diseases predisposing to sudden death. J Am Coll Cardiol 2002;40:359.

    Google Scholar 

  27. Meyer UA. Pharmacogenetics and adverse drug reactions. Lancet 2000;356:1667–1671.

    Google Scholar 

  28. Roden DM, George AL, Jr. The genetic basis of variability in drug responses. Nature Reviews Drug Discovery 2002;1:37–44.

    Google Scholar 

  29. Roses AD. Pharmacogenetics and the practice of medicine. Nature 2000;405:857–865.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Clinical Pharmacology, Vanderbilt University School of Medicine, Nashville, TN, 37232, USA

    Dan M. Roden (Director)

Authors
  1. Dan M. Roden
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dan M. Roden.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Roden, D.M. Genetic Polymorphisms, Drugs, and Proarrhythmia. J Interv Card Electrophysiol 9, 131–135 (2003). https://doi.org/10.1023/A:1026267903800

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1026267903800

Search

Navigation